Organisation paid for research Program year 2025 Source: CMS Open Payments

PPD Development LP

Neither a doctor nor a teaching hospital

Research payments

$68,813,860

673 payments

Through program year 2025, PPD Development LP is reported as receiving $68,813,860 in research payments, across 673 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$22,786,317	150
2024	Research	$10,868,815	88
2023	Research	$11,713,080	182
2022	Research	$12,514,524	140
2021	Research	$8,463,560	80
2020	Research	$1,419,117	17
2019	Research	$1,048,447	16

Breakdown

Who paid Research payments · program years 2019–2025

ViiV Healthcare Company $25,704,551 234 payments
GlaxoSmithKline, LLC. $24,327,367 223 payments
Janssen Research & Development, LLC $6,750,471 42 payments
AbbVie, Inc. $2,865,368 42 payments
Deciphera Pharmaceuticals Inc. $2,263,748 53 payments
Noven Pharmaceuticals, Inc. $1,729,592 13 payments
Pfizer Inc. $1,234,475 20 payments
Dova Pharmaceuticals $1,028,829 3 payments
Endo Pharmaceuticals Inc. $848,990 14 payments
Eli Lilly and Company $790,816 3 payments

Studies the money was for Research payments · program years 2019–2025

A Phase I, Multi-Centre, Open-Label, Single Dose Escalation Study to E $8,996,569 80 payments
A Phase 1 Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Random $6,432,911 28 payments
A Phase 1, Multi-Part, Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-88545223 in Healthy Non-Japanese and Japanese Participants i $6,256,792 37 payments
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Stu $4,947,267 30 payments
A Phase 1, Open-Label, Study of the Safety and Pharmacokinetics of A H $3,492,211 30 payments
An Open-Label, Randomized, Single-Dose, Multicenter, Parallel-Group St $3,447,950 37 payments
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Inves $3,132,824 25 payments
A Pharmacokinetic, Multi-Cohort Study in Healthy Adult Subjects to Ass $2,816,934 21 payments
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel Grou $2,544,470 17 payments
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Grou $2,424,778 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.